Deutsch English Espaniol

Curriculum vitae Dr. rer. nat. Ulf Vogt

Name Ulf Vogt, Dr. rer. nat. Diplom Biochemiker
Year of Birth 1964
e-mail druvogt@indivicon.org
Office Address European Laboratory Association/ Section Ibbenbüren,
Germany (Molecular Medicine and Tumor Prognosis)
Roggenkampstr. 12
49477 Ibbenbüren
Germany
Title and Affiliation:
a.) Owner and Head of the European Laboratory Association, Germany (Institute for Molecular Medicine and Tumor Prognosis)
Roggenkampstr. 12
49477 Ibbenbüren
Germany
b.) Dept. of Biotechnology
Universitiy of Gdansk
ul Kladki 24
80-822 Gdansk
Poland
Academic Appointments:
1986 degree for information science
1988 pre-degree in biology
1991 academic title as Diplom-Biochemiker
1994 academic title as Dr. rer. nat.

Bibliography:

Published and accepted articles in referred journals (most important):

  1. Kemming D, Vogt U, Tidow N, Schlotter CM, Bürger H, Helms MW, Korsching E, Granetzny A, Boseila A, Hillejan L, Marra A, Ergönenc Y, Adigüzel H, Brandt B.Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction. Mol Diagn Ther. 2006;10(5):271-80. Review.

  2. Granetzny A, Boseila A, Wagner W, Krukemeyer G, Vogt U, Hecker E, Koch OM, Klinke F.Surgery in the tri-modality treatment of small cell lung cancer. Stage-dependent survival.Eur J Cardiothorac Surg. 2006 Aug;30(2):212-6. Epub 2006 Jul 7.

  3. Vogt U, Bielawski KP, Bosse U, Schlotter CM;Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 2004 Nov;12(5):1109-14.

  4. Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, Schneider PM, Buchner T, Brandts C, Berdel WE, Serve H; High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets; Clin Cancer Res. 2004 Feb 15;10(4):1241-9.

  5. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 2003;5(2):R30-6

  6. Granetzny A, Striehn E, Bosse U, Wagner W, Koch O, Vogt U, Froeschle P, Klinke F. A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer.Ann Thorac Surg. 2003 Apr;75(4):1107-12.

  7. Muller-Tidow C, Diederichs S, Schrader MG, Vogt U, Miller K, Berdel WE, Serve H. Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. Cancer Lett 2003 Feb 10;190(1):89-95

  8. U.Vogt A.Zaczek F.Klinke A.Granetzny K.Bielawski B.Falkiewicz, p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer; J Cancer Res Clin Oncol 2002 Mar;128(3):141-7.

  9. Muller-Tidow C, Kugler K, Diederichs S, Klumpen S, Moller M, Vogt U, Metzger R, Schneider PM, Berdel WE, Serve H, Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. Br J Cancer. 2001 Oct 19;85(8):1168-74

  10. Falkiewicz B, Schlotter CM, Bosse U, Bielawski K, Vogt U,c-myc oncogene gene dosage, serum CEA and CA-15.3 antigen levels, and cellular DNA values in relation to ex vivo chemosensitivity of primary human breast cancer. Acta Biochim Pol. 2000;47(1):149-56.

  11. Vogt U, Falkiewicz B, Bielawski K, Bosse U, Schlotter CM.,Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.Acta Biochim Pol. 2000;47(1):157-64.

  12. Vogt U, Striehn E, Bosse U; Klinke F; Falkiewicz B, Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay,Acta Biochim Pol. 1999;46(2):299-302.

  13. Beckmann A, Vogt U, Huda N, Zaenker KS, Brandt BH, Direct-double-differential PCR for gene dosage quantification of c-myc. Clin Chem. 1999 Jan;45(1):141-3.

  14. Vogt U; Bielawski K, Schlotter CM, Bosse U, Falkiewicz B, Pohajska AJ Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene. 1998 Nov 26;223(1-2):375-80.

  15. Brandt, B., Vogt, U. et al Double-Differential PCR for gene dosages esimination of erb B- oncogenes in benign and cancer tissues and comparison to cellular DNA content; Gene, Vol. 159/95, 29-34

  16. Brandt, B.; Vogt, U. et al. Prognostic Relevance of aberrations of the erb B oncogenes in breast, ovarian, oral, and lung cancer: Double Differential Polymerase chain reaction (ddPCR) for clinical diagnosis; Gene, Gene, Vol. 159/95, 35-42

Books: (most important)

  1. Vogt, U., Schlotter, C.M., Bosse U., The influence of New Molecular Biological Parameters on Prognosis and Assesement in Primary Breast Cancer, Urban&Fischer; ISBN 3-437-21726-7, 147-160; 1999

  2. Kemming, D., Vogt U., Tidow N., Raem A., Brandt B.; Immunoassays; Immuno-chemilumineszensverfahren: Anwedung für die semiquantitative Genexpressionsanalyse des gesamten menschlichen Genoms; Elsevier; ISBN 10:3-8274-1636-1; 178-186; 2007

  3. Vogt U., Allgayer H.; Schlotter C.M.; Individualisierte Konzepte der primär systemischen und adjuvanten Therapie der Mammakarzinoms- Gen und Genexpression; Targeted therapies; Uni-med; ISBN: 978-3-86599-913-0; 187-198; 2007

  4. Schlotter C.M., Wassmann K., Poggemann A., Vogt U., Muhs H.J., v.d.Assen A.;; Individualisierte Konzepte der primär systemischen und adjuvanten Therapie der Mammakarzinoms- Gen und Genexpression; Neoadjuvante oder primär systemische Therapie des primären Mammakarzioms; Uni-med; ISBN: 978-3-86599-913-0; 82-135; 2007

« Zurück